Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

1. Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583–90. doi: 10.1002/mds.25945 24976103

2. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free radical biology & medicine. 2013 Sep;62:132–44.

3. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology. 2006 May 23;66(10 Suppl 4):S24–36. 16717250

4. Carta AR, Frau L, Pisanu A, Wardas J, Spiga S, Carboni E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model. Neuroscience. 2011 Oct 27;194:250–61. doi: 10.1016/j.neuroscience.2011.07.046 21839812

5. Sadeghian M, Marinova-Mutafchieva L, Broom L, Davis JB, Virley D, Medhurst AD, et al. Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. Journal of neuroimmunology. 2012 May 15;246(1–2):69–77. doi: 10.1016/j.jneuroim.2012.03.010 22498097

6. Hetzel M, Walcher D, Grub M, Bach H, Hombach V, Marx N. Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. Thorax. [Research Support, Non-U.S. Gov't]. 2003 Sep;58(9):778–83. 12947137

7. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. British journal of clinical pharmacology. 2010 Jan;69(1):4–14. doi: 10.1111/j.1365-2125.2009.03537.x 20078607

8. Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. British journal of clinical pharmacology. 1998 May;45(5):419–25. 9643612

9. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Therapeutic Advances in Drug Safety. 2012 Apr;3:89–99. doi: 10.1177/2042098611435911 25083228

10. van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AM, et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking. PLoS ONE. [Research Support, Non-U.S. Gov't]. 2014;9(4):e95297. doi: 10.1371/journal.pone.0095297 24788751

11. Morens DM, Grandinetti A, Reed D, White LR, Ross GW. Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology. [Research Support, U.S. Gov't, P.H.S.Review]. 1995 Jun;45(6):1041–51. 7783862

12. Dye RV, Miller KJ, Singer EJ, Levine AJ. Hormone replacement therapy and risk for neurodegenerative diseases. International journal of Alzheimer's disease. 2012;2012:258454. doi: 10.1155/2012/258454 22548198

13. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. [Comparative Study]. 2008 Apr 15;70(16 Pt 2):1438–44. doi: 10.1212/01.wnl.0000303818.38960.44 18256367

14. Marras C, Hincapie CA, Kristman VL, Cancelliere C, Soklaridis S, Li A, et al. Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Archives of physical medicine and rehabilitation. [Research Support, Non-U.S. Gov't Review]. 2014 Mar;95(3 Suppl):S238–44. doi: 10.1016/j.apmr.2013.08.298 24581909

15. Litvan I, Halliday G, Hallett M, Goetz CG, Rocca W, Duyckaerts C, et al. The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. Journal of neuropathology and experimental neurology. [Review]. 2007 Apr;66(4):251–7. 17413315

16. Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, Tuomilehto J. Body mass index and the risk of Parkinson disease. Neurology. [Comparative Study Research Support, Non-U.S. Gov't]. 2006 Dec 12;67(11):1955–9. 17159100

17. Lu L, Fu DL, Li HQ, Liu AJ, Li JH, Zheng GQ. Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies. PLoS ONE. 2014;9(1):e85781. doi: 10.1371/journal.pone.0085781 24465703

18. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism & related disorders. [Research Support, Non-U.S. Gov't]. 2012 Jul;18(6):753–8.

19. Sadeghian M, Camarata MA, Broom L, Bindra H, Davis JB, Medhurst AD, et al. Microglial activation in the 6-hydroxydopamine Parkinson's disease model is associated with a time dependent increase in neuronal expression of MMP-3 and MMP-9 and a dissociation of the CD200R neuronal/microglial complex. J Neuroinflammation.

20. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA: the journal of the American Medical Association. [Meta-Analysis]. 2007 Sep 12;298(10):1189–95.

21. U.S. Food and Drug Administration. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines FDA Drug Safety Communications [serial on the Internet]. [cited October 2014: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM381108.pdf.

22. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. [Research Support, Non-U.S. Gov't]. 2012;344:e3645. doi: 10.1136/bmj.e3645 22653981

23. Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB, et al. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer. Pharmacoepidemiology and drug safety. 2014 Jun;23(6):636–45. doi: 10.1002/pds.3619 24764283

24. Randy LH, Guoying B. Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Current neuropharmacology. 2007 Mar;5(1):35–46. 18615152

25. Pagel-Langenickel I, Bao J, Joseph JJ, Schwartz DR, Mantell BS, Xu X, et al. PGC-1alpha integrates insulin signaling, mitochondrial regulation, and bioenergetic function in skeletal muscle. The Journal of biological chemistry. 2008 Aug 15;283(33):22464–72. doi: 10.1074/jbc.M800842200 18579525

26. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochemistry international. 2009 Dec;55(7):496–504. doi: 10.1016/j.neuint.2009.05.001 19442697

27. Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, et al. Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Experimental neurology. 2011 Jan;227(1):128–35. doi: 10.1016/j.expneurol.2010.10.003 20965168

28. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med. [Meta-Analysis Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2010 Oct 6;2(52):52ra73.

29. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 2011 Mar 4;144(5):689–702. doi: 10.1016/j.cell.2011.02.010 21376232

30. Hernan MA, Logroscino G, Rodriguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. Journal of neurology. 2004 Oct;251 Suppl 7:vII14–7. 15505749